

P20637.A08

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : K. TSUGANEZAWA

Art Unit: Not Known

Appl. No. : 09/744,989

Examiner: Not Known

I. A. Filed : August 20, 1999

: EPIMORPHIN OF THE ORDER ARTIODACTYLA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks
Washington, DC 20231

Sir:



Further to the Information Disclosure Statement filed June 14, 2001, and pursuant to the duty of disclosure set forth in 37 C.F.R. 1.56 and in accordance with the provisions of 37 C.F.R. 1.97 and 1.98, the following additional information is brought to the attention of the Examiner, which information was cited in a Supplementary Partial European Search Report issued in connection with the counterpart European application.

U.S. Patent No. 5,837,239, which is a family member of previously cited U.S. Patent No. 5,726,298

JP 6-293800A accompanied by an English language abstract.

HIRAI et al., "Epimorphin: A Mesenchymal Protein Essential for Epithelial Morphogenesis", Cell, Vol. 69, pp. 471-481 (1992)

HIRAI, "Molecular Cloning of Human Epimorphin: Identification of Isoforms and Their Unique Properties", Biochemical Biophysical Research Communications, Vol. 191, No. 3, pp. 1332-1337 (1993)



P20637.A08

HIRAI et al., "Epimorphin Functions as a Key Morphoregulator for Mammary Epithelial Cells", The Journal of Cell Biology, Vol. 140, pp. 159-169 (1998)

ZHA et al., "The Epimorphin Gene is Highly Conserved among Humans, Mice, and Rats and Maps to Human Chromosome 7, Mouse Chromosome 5, and Rat Chromosome 12", Genomics, 37, pp. 386-389 (1996)

It is noted that only copies of U.S. Patent No. 5,837,239, and JP 6-293800A and its English language abstract are enclosed, because copies of the other documents have been previously submitted with the Information Disclosure Statement. Each of U.S. Patent No. 5,837,239, and JP 6-293800A and its English language abstract are listed on the attached Form PTO-1449 to permit the Examiner to indicate consideration thereof.

The Examiner is respectfully requested to consider the documents cited above and to confirm such consideration by initialling in the appropriate spaces on the Form PTO-1449 and returning a copy of the initialed form to Applicant.

Applicant notes that an Office Action on the Merits has not issued in the instant application. However, if an Office Action on the Merits has issued, and is crossing this statement in the mail, the undersigned hereby authorizes the Commissioner to charge any fee necessary for consideration of this statement, including any payment under 37 C.F.R. 1.17(p), to be charged to Deposit Account No. 19-0089.

The disclosure of the above documents does not constitute an admission that any particular document is relevant or material to the claims, or is prior analogous art with respect to the present


P20637.A08

application. The citation of these documents is not to be construed as a representation that no better art exists, or that a search has been made.

Any comments or questions concerning this application can be directed to the undersigned at the telephone number given below.

January 3, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Respectfully Submitted,
K. TSUGANEZAWA



Bruce H. Bernstein
Reg. No. 29,027

Reg No 33,094

RECEIVED
JAN 15 2002
TC 1700